Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919936 | 0.88 | TYR (0.39) | — | |
| SCHEMBL920666 | 0.86 | LIPG (0.44) | — | |
| SCHEMBL920907 | 0.85 | LIPG (0.47) | — | |
| SCHEMBL920584 | 0.85 | LIPG (0.47) | — | |
| SCHEMBL455634 | 0.83 | — | — | |
| SCHEMBL5209928 | 0.79 | BID (0.41) | — | |
| SCHEMBL27899130 | 0.79 | TDP1 (0.33) | TAAR1 | |
| SCHEMBL19405593 | 0.78 | SLC6A2 (0.31) | — | |
| SCHEMBL381275 | 0.77 | DAO (0.31) | DAO | |
| SCHEMBL487303 | 0.77 | GRM5 (0.36) | TAAR1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448259-B1 | CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | claimed |
| US-20240109883-A1 | Anti-Tumor Compositions and Methods | EVRYS BIO, LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230416241-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4271675-A1 | ANTI-TUMOR COMPOSITIONS AND METHODS | Evrys Bio, LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022147210-A1 | ANTI-TUMOR COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11358961-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| EP-2763533-B1 | TRIAZOLYL PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-105777776-B | Inhibitors of protein tyrosine kinase activity | 梅特希尔基因公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004035571-A1 | SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | METHYLGENE, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004035525-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2004-04-29 | — | — | WO | disclosed |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-20030225112-A1 | Inhibitors to tubulin polymerization | RIGEL PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003070241-A1 | INHIBITORS OF TUBULIN POLYMERIZATION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416241-A1 | Broad Spectrum Antiviral Compositions and Methods | IRF3, MAVS, ZC3HAV1 | TAAR1 3779/4885DAO 2810/4885 |
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | TAAR1 3779/4885DAO 2810/4885 |
| US-11358961-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | TAAR1 4748/4885DAO 3875/4885 |
| US-20030225112-A1 | Inhibitors to tubulin polymerization | TUBB3, TUBB1, TUBB | TAAR1 4609/4885DAO 3251/4885 |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, COASY | TAAR1 4628/4885DAO 111/4885 |
| US-20240109883-A1 | Anti-Tumor Compositions and Methods | DDX5, IRF3, TP53 | TAAR1 3935/4885DAO 3507/4885 |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | TAAR1 4748/4885DAO 3875/4885 |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | LSS, MGAM, COASY | TAAR1 4641/4885DAO 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.